Description:
This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 in patients with CLL/SLL and NHL who have failed or are intolerant to standard of care.
This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 in patients with CLL/SLL and NHL who have failed or are intolerant to standard of care.
Recruiting
Phase 1/Phase 2
Drug | Synonyms | Arms |
---|---|---|
LOXO-305 | Phase 1 Dose Expansion (LOXO-305 Monotherapy) | |
Venetoclax | Venclexta, Venclyxto | Phase 1b Dose Expansion (LOXO-305 Combination Therapy) Arm A |
Rituximab | Rituxan, MabThera | Phase 1b Dose Expansion (LOXO-305 Combination Therapy) Arm B |
This study includes 3 parts: phase 1 (LOXO-305 monotherapy dose escalation and dose expansion), phase 1b (LOXO-305 combination therapy dose expansion), and phase 2 (LOXO-305 monotherapy dose expansion). In phase 1, patients will be enrolled using an accelerated titration design. The starting dose of LOXO-305 in oral tablet form is 25 mg/day (e.g., 25 mg once daily [QD]). Once the MTD and/or RP2D is identified in phase 1 dose escalation, enrollment will continue to phase 1 dose expansion and can commence to phase 1b (Arms A and B). For phase 2, patients will be enrolled to one of seven phase 2 dose expansion cohorts depending on tumor histology and prior treatment history. Cycle length will be 28 days.
Name | Type | Description | Interventions |
---|---|---|---|
Phase I Dose Escalation (LOXO-305) Monotherapy) | Experimental | Dose Escalation and determination of MTD; multiple dose levels of LOXO-305 to be evaluated |
|
Phase 2 (LOXO-305 Monotherapy) Cohort 3 | Experimental | CLL/SLL patients with no prior therapy. |
|
Phase 2 (LOXO-305 Monotherapy) Cohort 1 | Experimental | Non-blastoid MCL patients treated with a prior BTK-inhibitor containing regimen. |
|
Phase 2 (LOXO-305 Monotherapy) Cohort 4 | Experimental | CLL/SLL patients treated with prior therapy, BTK inhibitor naïve. |
|
Phase 2 (LOXO-305 Monotherapy) Cohort 2 | Experimental | CLL/SLL patients treated with 2 or more prior regimens, including a BTK inhibitor-containing regimen. |
|
Phase 2 (LOXO-305 Monotherapy) Cohort 5 | Experimental | WM patients treated with a prior BTK inhibitor-containing regimen. |
|
Phase 2 (LOXO-305 Monotherapy) Cohort 6 | Experimental | MZL patients treated with a prior BTK inhibitor-containing regimen. |
|
Phase 2 (LOXO-305 Monotherapy) Cohort 7 | Experimental | (Not otherwise specified) Defined as CLL/SLL or NHL not otherwise specified in Cohorts 1 through 6, inclusive of CLL/SLL, Richter's transformation, or low grade NHL with transformation, blastoid MCL, and patients with history of CNS involvement or primary CNS lymphoma. In the event the Sponsor electively closes Cohorts 2-4 prior to completion, patients with CLL/SLL who are ineligible to participate in or unable to access late Phase studies of LOXO-305 would remain eligible to enroll in this cohort. |
|
Phase 1b Dose Expansion (LOXO-305 Combination Therapy) Arm A | Experimental | Relapsed/Refractory CLL will receive the recommended Phase 2 dose of LOXO-305 in combination with Venetoclax |
|
Phase 1b Dose Expansion (LOXO-305 Combination Therapy) Arm B | Experimental | Relapsed/Refractory CLL will receive the recommended Phase 2 dose of LOXO-305 in combination with Venetoclax and Rituximab |
|
Phase 1 Dose Expansion (LOXO-305 Monotherapy) | Experimental | Patients to receive the recommended Phase 2 dose of LOXO-305. |
|
Inclusion Criteria: - Histologically confirmed CLL/SLL, WM, or NHL intolerant to either ≥ 2 prior standard of care regimens given in combination or sequentially OR have received 1 prior BTK inhibitor-containing regimen when a BTK inhibitor is approved as first line therapy (Phase 1) OR with prior treatment defined by phase 2 cohort (Phase 2 Patients only). - Adequate hematologic function (Phase 1 and 1b Patients only). - Responsive to transfusion support if given for thrombocytopenia or anemia (Phase 1 and 1b Patients only). - Histologically confirmed relapsed/recurrent CLL in whom venetoclax is appropriate standard salvage treatment; no prior venetoclax is permitted (Phase 1b Arm A Patients only). - Histologically confirmed relapsed/refractory CLL in whom venetoclax + rituximab is appropriate standard salvage treatment; no prior venetoclax is permitted (Phase 1b Arm B Patients only). - Eastern Cooperative Oncology Group (ECOG) 0-2. - Adequate hepatic and renal function. - Ability to receive study drug therapy orally. - Willingness of men and women of reproductive potential (defined as following menarche and not postmenopausal [and 2 years of non-therapy-induced amenorrhea] or surgically sterile) to observe conventional and effective birth control. Exclusion Criteria: - Investigational agent or anticancer therapy within 5 half-lives prior to planned start of specified study therapy except therapeutic monoclonal antibody treatment must be discontinued a minimum of 4 weeks prior to the first dose of LOXO-305. In addition, no concurrent systemic anticancer therapy is permitted. - Major surgery within 4 weeks prior to planned start of specified study therapy. - Radiotherapy with a limited field of radiation for palliation within 7 days of the first dose of study treatment. - Pregnancy or lactation. - Patients requiring therapeutic anticoagulation with warfarin. - Any unresolved toxicities from prior therapy greater than CTCAE (version 5.0) Grade 2 or greater at the time of starting study treatment except for alopecia. - History of allogeneic or autologous stem cell transplant (SCT) or chimeric antigen receptor-modified T-cell (CAR-T) therapy within the past 60 days (180 days before the PK trigger) prior to planned start of specified study therapy. - Known central nervous system (CNS) involvement by systemic lymphoma. Patients with previous treatment for CNS involvement who are neurologically stable and without evidence of disease may be eligible and enrolled to phase 2 Cohort 7 if a compelling clinical rationale is provided by the Investigator and with documented Sponsor approval. - Active uncontrolled auto-immune cytopenia where new therapy introduced or concomitant therapy escalated within the 4 weeks prior to study enrollment is required to maintain adequate blood counts. - Clinically significant, uncontrolled cardiac, cardiovascular disease or history of myocardial infarction within 6 months prior to planned start of LOXO-305. - Active uncontrolled systemic bacterial, viral, fungal or parasitic infection. - Patients who have tested positive for Human Immunodeficiency Virus (HIV) are excluded. For patients with unknown HIV status, HIV testing will be performed at Screening and result should be negative for enrollment. - Clinically significant active malabsorption syndrome. - Current treatment with certain strong CYP3A4 inhibitors or inducers and/or strong P-gp inhibitors. - For patients enrolled to phase 1b Arm A or B: Patients with prior treatment with venetoclax or other BCL-2 inhibitors. - Prior treatment with LOXO-305. - Active second malignancy unless in remission and with life expectancy > 2 years. - Known hypersensitivity to any component or excipient of LOXO-305. - For patients enrolled to phase 1b Arm B: Patients with prior significant hypersensitivity, allergy, or anaphylactic reaction to rituximab/biosimilar requiring discontinuation. - Patients with prior significant hypersensitivity to rituximab requiring discontinuation, prior allergic or anaphylactic reaction to rituximab (Phase 1b Arm B Patients only).
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Measure: | Maximum Tolerated Dose (MTD) |
Time Frame: | Up to 24 Months |
Safety Issue: | |
Description: | Phase I |
Measure: | To determine the safety profile and tolerability of LOXO-305 including acute and chronic toxicities by collecting and evaluating Adverse events and treatment emergent adverse events. |
Time Frame: | Up to 24 Months |
Safety Issue: | |
Description: | Phase I |
Measure: | To characterize the pharmacokinetics (PK) properties of LOXO-305 by collecting and evaluating serum at protocol specified time points. |
Time Frame: | Up to 24 Months |
Safety Issue: | |
Description: | Phase I |
Measure: | To assess the preliminary anti-tumor activity of LOXO-305 based on overall response rate (ORR) as assessed by investigator. |
Time Frame: | Up to 24 Months |
Safety Issue: | |
Description: | Phase I |
Measure: | ORR as assessed by the Investigator. |
Time Frame: | Up to 24 Months |
Safety Issue: | |
Description: | Phase II |
Measure: | Best overall response (BOR) as assessed by the Investigator and IRC. |
Time Frame: | Up to 24 Months |
Safety Issue: | |
Description: | Phase II |
Measure: | Duration of response (DOR) as assessed by the Investigator and IRC. |
Time Frame: | Up to 24 Months |
Safety Issue: | |
Description: | Phase II |
Measure: | Progression free survival (PFS) as assessed by the Investigator and IRC. |
Time Frame: | Up to 24 Months |
Safety Issue: | |
Description: | Phase II |
Measure: | Overall survival (OS). |
Time Frame: | Up to 24 Months |
Safety Issue: | |
Description: | Phase II |
Measure: | To determine the safety profile and tolerability of LOXO-305 including acute and chronic toxicities by collecting and evaluating Adverse events and treatment emergent adverse events |
Time Frame: | Up to 24 Months |
Safety Issue: | |
Description: | Phase II |
Measure: | To characterize the pharmacokinetics (PK) properties of LOXO-305 by collecting and evaluating serum at protocol specified time points. |
Time Frame: | Up to 24 Months |
Safety Issue: | |
Description: | Phase II |
Measure: | To characterize the pharmacokinetics (PK) properties of LOXO-305 by collecting and evaluating serum at protocol specified time points. |
Time Frame: | Up to 24 months |
Safety Issue: | |
Description: | For Phase 1b |
Measure: | To assess the preliminary anti-tumor activity of LOXO-305 in combination based on overall response rate (ORR) as assessed by investigator. |
Time Frame: | Up to 24 months |
Safety Issue: | |
Description: | For Phase 1b |
Measure: | Symptomatic Response: Change from Baseline in Mantle Cell Lymphoma (MCL)-related symptoms selected from the European Organisation for Research and Treatment of Cancer (EORTC) Item Library |
Time Frame: | Baseline, End of Treatment (Estimated Up to 24 Months) |
Safety Issue: | |
Description: | Individual EORTC symptom scores range from 1 (not at all) to 4 (very much) with higher scores representing more severe symptom severity. |
Measure: | Functional Response: Change from Baseline in Physical Functioning as Measured by Physical Functioning Scale from the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Version 3.0 (EORTC QLQ) |
Time Frame: | Baseline, End of Treatment (Estimated Up to 24 Months) |
Safety Issue: | |
Description: | EORTC physical function item scores range from 1 (not at all) to 4 (very much) with higher scores indicating poorer functioning.The total EORTC physical functioning score ranges from 0-100 where a higher score indicates higher/healthier level of functioning. |
Phase: | Phase 1/Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | Loxo Oncology, Inc. |
July 23, 2021